The pCR rates in the ADAPT study were 41.0% for the T-DM1×4 regimen and 41.5% for the T-DM1+ET×4 regimen in patients with early HER2+ HR+ breast cancer [20]. This evidence concerns the gene ERBB2 and breast cancer.